CCA
RAPP

Cygnus Capital Advisors’s Rapport Therapeutics RAPP Stock Holding History

Cygnus Capital Advisors’s Portfolio RAPP Stock Details RAPP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-341
Closed -$10 – 187
2025
Q4 		$10 Buy
+341
New +$9.44K 0.01% 105

Other funds holding RAPP

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TGV
TRV GP V Boston, Massachusetts $498M AUM 267.53% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

Cygnus Capital Advisors's RAPP Position: Q1 2026 in Review

Cygnus Capital Advisors sold out of Rapport Therapeutics (RAPP) in Q1 2026, closing a stake of 341 shares — an estimated $10 sold.

Cygnus Capital Advisors first reported a position in RAPP in Q4 2025 and held it in 1 quarter. The position peaked at $10 in Q4 2025. 147 funds tracked by Wall St. Rank hold RAPP as of Q1 2026.

  • Cygnus Capital Advisors reported no remaining Rapport Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Cygnus Capital Advisors sold 341 Rapport Therapeutics shares in Q1 2026, an estimated $10.
  • Cygnus Capital Advisors first reported a position in Rapport Therapeutics in Q4 2025 and held it in 1 quarter.
  • Cygnus Capital Advisors's Rapport Therapeutics position peaked at $10 in Q4 2025.
  • 147 funds tracked by Wall St. Rank held Rapport Therapeutics as of Q1 2026.

Based on Cygnus Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.